Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Neoplasms 3217Carcinoma, Non-Small-Cell Lung 2731Breast Neoplasms 2553Colorectal Neoplasms 1464Prostatic Neoplasms 1310Neoplasm Metastasis 1302Multiple Myeloma 1112Melanoma 1102Ovarian Neoplasms 1006Lung Neoplasms 946Recurrence 924Leukemia, Myeloid, Acute 878Pancreatic Neoplasms 833Lymphoma, Non-Hodgkin 767Lymphoma 713Stomach Neoplasms 693Carcinoma, Renal Cell 661Carcinoma, Hepatocellular 648Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 550Lymphoma, Follicular 516Head and Neck Neoplasms 491Glioblastoma 473Small Cell Lung Carcinoma 447Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 436Advanced Solid Tumors 433Leukemia 426Uterine Cervical Neoplasms 420Urinary Bladder Neoplasms 405

Interventions

3-ingenyl angelate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Melanosis × Clear all
NCT00375739 2016-01-28

Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses

Peplin

Phase 2 Completed
200 enrolled
Dermatologic

Melanosis, Keratosis, Actinic

NCT00107965 2015-03-25

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses

Peplin

Phase 2 Completed
60 enrolled
Dermatologic

Melanosis, Keratosis, Actinic

NCT00239135 2015-03-25

Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel

Peplin

Phase 2 Completed
34 enrolled
Dermatologic

Keratosis, Melanosis, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡